<DOC>
	<DOCNO>NCT02355951</DOCNO>
	<brief_summary>Objectives : Primary Objective : To identify preselect patient chronic HBV mono infection , undetectable anti-Ad5 nAb , currently treat nucleo ( ) side , participation TG1050.02 Phase1/1b First Man ( FIM ) study . Secondary Objectives : To assess prevalence undetectable anti-Ad5 nAb chronic HBV mono-infected patient . Methodology : Patients chronic HBV mono-infection , currently treat nucleo ( ) side HBV infection , enrol study measure Ad5 nAb level . A single peripheral blood collection ( 4 mL ) obtain Ad5 nAb titer measure central laboratory use newly validate assay .</brief_summary>
	<brief_title>Non-investigational Study Evaluate Adenovirus Serotype 5 ( Ad5 ) Neutralizing Antibodies ( nAb ) Patients With Chronic Hepatitis B Virus ( HBV ) Mono-infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>18 65 year age , inclusive Patients monoinfected HBV currently HBV treatment least 2 year either nucleos ( ) ide tenofovir ( TDF ) entecavir ( ENT ) HBV DNA &lt; low limit quantification ( LLOQ ) ( eg , HBV deoxyribonucleic acid ( DNA ) &lt; 20 IU/mL use Roche COBAS TaqMan assay ) within 6 last month Signed , write Independent Ethics Committee ( IEC ) approve informed consent Patients either medical history evidence cirrhosis , document medical source , : ) biopsy show cirrhosis ; b ) transient elastography score ≥ 10.5 kPa Fibrosure® / FibroTest ® score ≥ 0.48 either test result within past 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>